Abstract | IMPORTANCE: OBJECTIVE: DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included patients with metastatic RCC and brain metastases treated in 15 international institutions (US, Belgium, France, and Spain) between January 2014 and October 2020. Cohort A comprised patients with progressing brain metastases without concomitant brain-directed local therapy, and cohort B comprised patients with stable or progressing brain metastases concomitantly treated by brain-directed local therapy. EXPOSURES: Receipt of cabozantinib monotherapy at any line of treatment. MAIN OUTCOMES AND MEASURES: Intracranial radiological response rate by modified Response Evaluation Criteria in Solid Tumors, version 1.1, and toxic effects of cabozantinib. RESULTS: Of the 88 patients with brain metastases from RCC included in the study, 33 (38%) were in cohort A and 55 (62%) were in cohort B; the majority of patients were men (n = 69; 78%), and the median age at cabozantinib initiation was 61 years (range, 34-81 years). Median follow-up was 17 months (range, 2-74 months). The intracranial response rate was 55% (95% CI, 36%-73%) and 47% (95% CI, 33%-61%) in cohorts A and B, respectively. In cohort A, the extracranial response rate was 48% (95% CI, 31%-66%), median time to treatment failure was 8.9 months (95% CI, 5.9-12.3 months), and median overall survival was 15 months (95% CI, 9.0-30.0 months). In cohort B, the extracranial response rate was 38% (95% CI, 25%-52%), time to treatment failure was 9.7 months (95% CI, 6.0-13.2 months), and median overall survival was 16 months (95% CI, 12.0-21.9 months). Cabozantinib was well tolerated, with no unexpected toxic effects or neurological adverse events reported. No treatment-related deaths were observed. CONCLUSIONS AND RELEVANCE:
|
Authors | Laure Hirsch, Nieves Martinez Chanza, Subrina Farah, Wanling Xie, Ronan Flippot, David A Braun, Nityam Rathi, Jonathan Thouvenin, Katharine A Collier, Emmanuel Seront, Guillermo de Velasco, Hannah Dzimitrowicz, Benoit Beuselinck, Wenxin Xu, I Alex Bowman, Elaine T Lam, Bashar Abuqayas, Mehmet Asim Bilen, Andreas Varkaris, Yousef Zakharia, Michael R Harrison, Amir Mortazavi, Philippe Barthélémy, Neeraj Agarwal, Rana R McKay, Priscilla K Brastianos, Katherine M Krajewski, Laurence Albigès, Lauren C Harshman, Toni K Choueiri |
Journal | JAMA oncology
(JAMA Oncol)
Vol. 7
Issue 12
Pg. 1815-1823
(Dec 01 2021)
ISSN: 2374-2445 [Electronic] United States |
PMID | 34673916
(Publication Type: Journal Article)
|
Chemical References |
- Anilides
- Pyridines
- cabozantinib
|
Topics |
- Anilides
(adverse effects)
- Brain Neoplasms
(drug therapy, secondary)
- Carcinoma, Renal Cell
(pathology)
- Cohort Studies
- Female
- Humans
- Kidney Neoplasms
(pathology)
- Male
- Prospective Studies
- Pyridines
(adverse effects)
- Retrospective Studies
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|